DTIL

Precision BioSciences, Inc. (DTIL) | Rumor.io

Precision BioSciences

DTIL

Attention (50-day avg)0%

Attention rank (50-day avg)#2,283

Bullish sentiment (50-day avg)88%

Price to earnings ratio4.38

Market capitalization172.2M

Earnings per share-1.31

Dividend yield (TTM)—

Revenue (annual)34.3M

Net income (annual)-45.7M

Social

What share of all stock conversation is about DTIL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 27

Precision BioSciences' gene editing technology has the potential to revolutionize the field of in vivo gene therapy.
The company's PBGENE-HBV treatment has shown promising results in eliminating cccDNA, a key factor in viral DNA replication, and may lead to a cure for hepatitis B.
A combination study with bepirovirsen and PBGENE-HBV could be a potential long-term strategy for Precision BioSciences, with GSK viewing bepirovirsen as a "backbone therapy" for HBV.

Generated by AI

Sentiment

Of the messages about DTIL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +20	85.82% +7.32
Bearish	—	0%	0% -20	14.18% -7.32

Bullish· Jun 25

$DTIL has a strong risk-reward profile with limited downside and limitless upside potential, with an analyst's target price of $60.
The FDA's rare pediatric disease designation for $DTIL provides a priority voucher and could lead to a significant increase in its market value.
$DTIL's low float, massive relative volume, and potential for a cure in its DMD program could drive its share price to $100 or more in the near future.

Bearish· Jun 25

* The company's stock price dropped over 5% despite positive news, suggesting a market environment where good news is not being rewarded.
* The stock's high volume of shares being traded, particularly after positive news, may indicate a large number of investors are eager to sell.
* The stock's price is experiencing bearish momentum, with the potential for a retest of support levels at $5.21.

Generated by AI

Topics

Of the messages about DTIL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	91.69%
Analysts	—	0%	0%	1.38%
Controversies	—	0%	0%	1.29%
Earnings	—	0%	0%	0.59%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	5.04%

Jun 25

Precision BioSciences, Inc. (DTIL) received FDA Rare Pediatric Disease Designation for its gene editing therapy, PBGENE-DMD, for the treatment of Duchenne muscular dystrophy.
This designation may make Precision BioSciences eligible to receive a Priority Review Voucher upon FDA approval of PBGENE-DMD.
Shares of Precision BioSciences rose 20% after the announcement, with the stock price jumping in pre-market trading.

Generated by AI

Community

Of the messages about DTIL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	97.3%	74.98%
Newcomers	0%	0%	2.7%	25.02%

Regulars· Jun 25

The FDA has granted Precision BioSciences Rare Pediatric Disease Designation for PBGENE-DMD, a gene editing therapy for Duchenne Muscular Dystrophy, which may make it eligible for a Priority Review Voucher upon approval.
Precision BioSciences' PBGENE-DMD has received FDA Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy, a condition affecting up to 60% of DMD patients, with the therapy aiming for near full-length dystrophin production.
The FDA's Rare Pediatric Disease Designation for PBGENE-DMD has the potential to significantly benefit DMD patients, with Precision BioSciences' stock price increasing by 19% in pre-market trading following the announcement.

Newcomers· Mar 9

$DTIL receives FDA Fast Track Designation for PBGENE-DMD in Duchenne Muscular Dystrophy, potentially accelerating development as a treatment.
The stock price surged 10% to $5.09 due to the FDA's Fast Track designation, with traders advised to watch for increased volatility.
Analyst price targets for $DTIL are around $32.50, a 12-month forecast based on the company's pipeline, data, and models, with some firms raising their projections sharply in recent months.

Generated by AI

News

Precision Biosciences director Geno Germano buys $16,384 in stock

23h agoInvesting.com

Precision Biosciences director Melinda Brown buys $7,116 in stock

23h agoInvesting.com

Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera

18d agobarchart.com

Precision BioSciences doses first patient in DMD gene editing trial

1mo agoInvesting.com

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

DURHAM, N.C., August 24, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

1mo agoYahoo Finance

Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL)

Precision BioSciences' direct clinical evidence and pipeline optionality outweigh the early-stage risks. Find out why DTIL stock is a speculative Buy.

1mo agoSeeking Alpha

Also Discussed

Investors talking about DTIL also mention

#	Name	Attention
1	Intellia Therapeutics, Inc.NTLA	0%+0
2	Beam Therapeutics IncBEAM	0.02%+0.02
3	PSTX - Poseida Therapeutics, Inc.	——
4	Alector Inc.ALEC	0%new
5	Caribou Biosciences, Inc.CRBU	0%new
6	CRISPR Therapeutics AGCRSP	0%-0.01
7	Cellectis S.A. ADRCLLS	0%new
8	Century Therapeutics IncIPSC	0%0
9	IDEAYA Biosciences Inc.IDYA	0%-0.01
10	Editas Medicine, Inc.EDIT	0%+0

Precision BioSciences, Inc.

Healthcare
Biotechnology

Precision BioSciences, Inc. is a clinical-stage gene editing company focused on developing in vivo therapies for serious diseases with limited treatment options. Its proprietary ARCUS® genome editing platform is designed to make precise changes to DNA and supports programs aimed at treating chronic hepatitis B, Duchenne muscular dystrophy, and other high-unmet-need conditions. The company’s current work centers on advancing therapeutic candidates through clinical development, with an emphasis on direct gene correction, elimination, or insertion in targeted tissues. Precision BioSciences serves the biotechnology and life sciences markets by applying its editing technology to human therapeutics, positioning itself as a specialist in next-generation genetic medicine from its headquarters in Durham, North Carolina.

Website

Location

302 East Pettigrew St.

Durham, NC, 27701

United States

Social

What share of all stock conversation is about DTIL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 27

Precision BioSciences' gene editing technology has the potential to revolutionize the field of in vivo gene therapy.
The company's PBGENE-HBV treatment has shown promising results in eliminating cccDNA, a key factor in viral DNA replication, and may lead to a cure for hepatitis B.
A combination study with bepirovirsen and PBGENE-HBV could be a potential long-term strategy for Precision BioSciences, with GSK viewing bepirovirsen as a "backbone therapy" for HBV.

Generated by AI

Sentiment

Of the messages about DTIL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +20	85.82% +7.32
Bearish	—	0%	0% -20	14.18% -7.32

Bullish· Jun 25

$DTIL has a strong risk-reward profile with limited downside and limitless upside potential, with an analyst's target price of $60.
The FDA's rare pediatric disease designation for $DTIL provides a priority voucher and could lead to a significant increase in its market value.
$DTIL's low float, massive relative volume, and potential for a cure in its DMD program could drive its share price to $100 or more in the near future.

Bearish· Jun 25

* The company's stock price dropped over 5% despite positive news, suggesting a market environment where good news is not being rewarded.
* The stock's high volume of shares being traded, particularly after positive news, may indicate a large number of investors are eager to sell.
* The stock's price is experiencing bearish momentum, with the potential for a retest of support levels at $5.21.

Generated by AI

Topics

Of the messages about DTIL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	91.69%
Analysts	—	0%	0%	1.38%
Controversies	—	0%	0%	1.29%
Earnings	—	0%	0%	0.59%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	5.04%

Jun 25

Precision BioSciences, Inc. (DTIL) received FDA Rare Pediatric Disease Designation for its gene editing therapy, PBGENE-DMD, for the treatment of Duchenne muscular dystrophy.
This designation may make Precision BioSciences eligible to receive a Priority Review Voucher upon FDA approval of PBGENE-DMD.
Shares of Precision BioSciences rose 20% after the announcement, with the stock price jumping in pre-market trading.

Generated by AI

Community

Of the messages about DTIL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	97.3%	74.98%
Newcomers	0%	0%	2.7%	25.02%

Regulars· Jun 25

The FDA has granted Precision BioSciences Rare Pediatric Disease Designation for PBGENE-DMD, a gene editing therapy for Duchenne Muscular Dystrophy, which may make it eligible for a Priority Review Voucher upon approval.
Precision BioSciences' PBGENE-DMD has received FDA Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy, a condition affecting up to 60% of DMD patients, with the therapy aiming for near full-length dystrophin production.
The FDA's Rare Pediatric Disease Designation for PBGENE-DMD has the potential to significantly benefit DMD patients, with Precision BioSciences' stock price increasing by 19% in pre-market trading following the announcement.

Newcomers· Mar 9

$DTIL receives FDA Fast Track Designation for PBGENE-DMD in Duchenne Muscular Dystrophy, potentially accelerating development as a treatment.
The stock price surged 10% to $5.09 due to the FDA's Fast Track designation, with traders advised to watch for increased volatility.
Analyst price targets for $DTIL are around $32.50, a 12-month forecast based on the company's pipeline, data, and models, with some firms raising their projections sharply in recent months.

Generated by AI

Precision BioSciences

Social

May 27

Bullish· Jun 25

Bearish· Jun 25

Jun 25

Regulars· Jun 25

Newcomers· Mar 9

Precision Biosciences director Geno Germano buys $16,384 in stock

Precision Biosciences director Melinda Brown buys $7,116 in stock

Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera

Precision BioSciences doses first patient in DMD gene editing trial

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL)

Also Discussed

Precision BioSciences, Inc.

Company Information

Location

Precision Biosciences director Geno Germano buys $16,384 in stock

Precision Biosciences director Melinda Brown buys $7,116 in stock

Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera

Precision BioSciences doses first patient in DMD gene editing trial

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL)

Also Discussed

Social

May 27

Bullish· Jun 25

Bearish· Jun 25

Jun 25

Regulars· Jun 25

Newcomers· Mar 9